Labcorp Q4 Earnings Beat Expectations, 2026 Outlook Positive
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy LH?
Source: seekingalpha
- Earnings Highlights: Labcorp's Q4 Non-GAAP EPS of $4.07 exceeded expectations by $0.13, indicating strong profitability, although revenue of $3.52 billion, up 5.7% year-over-year, fell short of market expectations by $40 million.
- Free Cash Flow Trends: The company reported Q4 free cash flow of $490.3 million, a significant drop from $665.1 million year-over-year, while full-year free cash flow reached $1.21 billion, surpassing the $1.10 billion forecast, reflecting effective cash management.
- 2026 Financial Guidance: Labcorp's guidance for 2026 enterprise revenue is set between $14.61 billion and $14.79 billion, with a midpoint growth of 5.4%, exceeding the $14.63 billion consensus, demonstrating confidence in future growth prospects.
- Earnings Per Share Outlook: The adjusted EPS guidance ranges from $17.55 to $18.25, with a midpoint growth of 8.9%, surpassing the market expectation of $17.52, indicating ongoing improvements in profitability and competitive positioning.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 264.200
Low
270.00
Averages
304.45
High
325.00
Current: 264.200
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration to advance precision oncology using next-generation sequencing (NGS) solutions, expected to promote equitable access to cancer biomarker testing and enhance patient convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic (IVD) tests, aiming to bridge gaps in precision oncology and drive advancements in personalized cancer care.
- Liquid and Tissue Biopsy Integration: The collaboration will explore co-commercializing Labcorp's FDA-authorized liquid biopsy PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, aiming to provide broader biomarker testing for hospitals and community health systems.
- Clinical Utility Research: In a joint study, Illumina's CGP detected variants in over 72% of more than 7,600 non-small cell lung cancer samples that had current targeted therapies or clinical trials, demonstrating CGP's effectiveness in identifying tumor genomic features.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration aimed at enhancing precision oncology through next-generation sequencing solutions, with expectations to promote equitable access to cancer biomarker testing, thereby improving patient testing convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic tests, aiming to bridge existing gaps in precision oncology and improve patient treatment outcomes.
- Co-Commercialization: Plans include co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, intended to provide broader access to both tissue and liquid biopsy testing for hospitals and community health systems.
- Clinical Utility Research: The companies will continue joint efforts to demonstrate the clinical utility of CGP, with studies showing that CGP detected variants in over 72% of non-small cell lung cancer patient tumors that are relevant to current targeted therapies or clinical trials, further advancing the application of precision medicine.
See More
Middleby Appoints Glenn Eisenberg to Board of Directors
- Board Expansion: The Middleby Corporation announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1, increasing the board to twelve members, which underscores the company's commitment to strategic transformation.
- Extensive Financial Experience: Eisenberg brings a 20-year track record as a public company CFO and senior operating executive, having previously served as CFO at Labcorp, overseeing financial operations in over 100 countries, which is expected to significantly support Middleby's operational initiatives.
- Strategic Focus: Middleby CEO Tim FitzGerald noted that Eisenberg's expertise in financial discipline and capital allocation will be crucial for driving sustainable organic growth, reflecting the company's emphasis on enhancing board capabilities.
- Diverse Leadership Background: Eisenberg currently serves on the boards of two other public companies and has extensive public company governance experience, which will provide valuable oversight for Middleby as it aims to achieve long-term value creation and operational excellence.
See More
LABCORP CEO ADAM SCHECHTER DISCLOSES SALE OF 8,705 COMMON SHARES ON MARCH 3 AT $279.9595 EACH, ACCORDING TO SEC FILING
Company Announcement: Labor Corp CEO Adam Schechter reports the open market sale of 8,705 common shares.
Sale Details: The shares were sold on March 3 at a price of $279.95 per share, as disclosed in a SEC filing.
See More
Five Key Principles of Innovation
- Importance of Innovation Culture: Lorraine Marchand emphasizes that successful organizations foster a culture that reframes failure as a learning opportunity, encouraging experimentation and allowing employees to freely express new ideas, thereby enhancing the organization's innovative capacity.
- Investment Strategy in Risk: She notes that successful companies often follow a 70/20/10 investment ratio, with 10% allocated to uncertain innovation projects, a strategy validated by Google's success, indicating that appropriate risk investment can significantly drive company growth.
- Customer-First Strategy: Marchand points out that many companies fail to adjust to changing customer demands, leading to market failures; therefore, investors should focus on a company's customer-oriented strategies to avoid failures similar to those of Blockbuster and Kodak.
- Collaboration and Change Management: She highlights that collaboration has become a strategic imperative for corporate success, and organizations need to prioritize team collaboration during change to achieve breakthrough growth, ensuring that departments work together towards common objectives.
See More
Labcorp Expands Collaboration with PathAI for Digital Pathology
- Digital Pathology Expansion: Labcorp announced an expansion of its collaboration with PathAI to deploy the FDA-cleared AISight Dx digital pathology platform across its national network of anatomic pathology labs and hospital collaborations, aiming to enhance the digitalization of pathology workflows.
- Cloud Workflow Support: The platform will support fully digital workflows for slide review, case management, and collaboration, integrating AI-powered image analysis technology to assist in diagnostics, thereby improving overall diagnostic accuracy.
- Precision Medicine Integration: Labcorp will also incorporate digital pathology workflows to support its precision medicine products, further advancing the company's strategic positioning in the personalized medicine sector.
- Continued Strategic Investment: This expansion builds on Labcorp's 2019 strategic investment in PathAI, indicating ongoing collaboration in AI-driven clinical trial support and validation of pathology solutions, which is expected to drive future growth for the company.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration to advance precision oncology using next-generation sequencing (NGS) solutions, expected to promote equitable access to cancer biomarker testing and enhance patient convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic (IVD) tests, aiming to bridge gaps in precision oncology and drive advancements in personalized cancer care.
- Liquid and Tissue Biopsy Integration: The collaboration will explore co-commercializing Labcorp's FDA-authorized liquid biopsy PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, aiming to provide broader biomarker testing for hospitals and community health systems.
- Clinical Utility Research: In a joint study, Illumina's CGP detected variants in over 72% of more than 7,600 non-small cell lung cancer samples that had current targeted therapies or clinical trials, demonstrating CGP's effectiveness in identifying tumor genomic features.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration aimed at enhancing precision oncology through next-generation sequencing solutions, with expectations to promote equitable access to cancer biomarker testing, thereby improving patient testing convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic tests, aiming to bridge existing gaps in precision oncology and improve patient treatment outcomes.
- Co-Commercialization: Plans include co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, intended to provide broader access to both tissue and liquid biopsy testing for hospitals and community health systems.
- Clinical Utility Research: The companies will continue joint efforts to demonstrate the clinical utility of CGP, with studies showing that CGP detected variants in over 72% of non-small cell lung cancer patient tumors that are relevant to current targeted therapies or clinical trials, further advancing the application of precision medicine.
See More
Middleby Appoints Glenn Eisenberg to Board of Directors
- Board Expansion: The Middleby Corporation announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1, increasing the board to twelve members, which underscores the company's commitment to strategic transformation.
- Extensive Financial Experience: Eisenberg brings a 20-year track record as a public company CFO and senior operating executive, having previously served as CFO at Labcorp, overseeing financial operations in over 100 countries, which is expected to significantly support Middleby's operational initiatives.
- Strategic Focus: Middleby CEO Tim FitzGerald noted that Eisenberg's expertise in financial discipline and capital allocation will be crucial for driving sustainable organic growth, reflecting the company's emphasis on enhancing board capabilities.
- Diverse Leadership Background: Eisenberg currently serves on the boards of two other public companies and has extensive public company governance experience, which will provide valuable oversight for Middleby as it aims to achieve long-term value creation and operational excellence.
See More
LABCORP CEO ADAM SCHECHTER DISCLOSES SALE OF 8,705 COMMON SHARES ON MARCH 3 AT $279.9595 EACH, ACCORDING TO SEC FILING
Company Announcement: Labor Corp CEO Adam Schechter reports the open market sale of 8,705 common shares.
Sale Details: The shares were sold on March 3 at a price of $279.95 per share, as disclosed in a SEC filing.
See More
Five Key Principles of Innovation
- Importance of Innovation Culture: Lorraine Marchand emphasizes that successful organizations foster a culture that reframes failure as a learning opportunity, encouraging experimentation and allowing employees to freely express new ideas, thereby enhancing the organization's innovative capacity.
- Investment Strategy in Risk: She notes that successful companies often follow a 70/20/10 investment ratio, with 10% allocated to uncertain innovation projects, a strategy validated by Google's success, indicating that appropriate risk investment can significantly drive company growth.
- Customer-First Strategy: Marchand points out that many companies fail to adjust to changing customer demands, leading to market failures; therefore, investors should focus on a company's customer-oriented strategies to avoid failures similar to those of Blockbuster and Kodak.
- Collaboration and Change Management: She highlights that collaboration has become a strategic imperative for corporate success, and organizations need to prioritize team collaboration during change to achieve breakthrough growth, ensuring that departments work together towards common objectives.
See More
Labcorp Expands Collaboration with PathAI for Digital Pathology
- Digital Pathology Expansion: Labcorp announced an expansion of its collaboration with PathAI to deploy the FDA-cleared AISight Dx digital pathology platform across its national network of anatomic pathology labs and hospital collaborations, aiming to enhance the digitalization of pathology workflows.
- Cloud Workflow Support: The platform will support fully digital workflows for slide review, case management, and collaboration, integrating AI-powered image analysis technology to assist in diagnostics, thereby improving overall diagnostic accuracy.
- Precision Medicine Integration: Labcorp will also incorporate digital pathology workflows to support its precision medicine products, further advancing the company's strategic positioning in the personalized medicine sector.
- Continued Strategic Investment: This expansion builds on Labcorp's 2019 strategic investment in PathAI, indicating ongoing collaboration in AI-driven clinical trial support and validation of pathology solutions, which is expected to drive future growth for the company.
See More
